Ovid Therapeutics Hosts Educational Webinar on Angelman Syndrome and OV101 Development Program Oct 22, 2020 1:00 PM EDT Click here for webcast
Press Releases Year None202020192018201720162015 Jul 23, 2020 Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome Jul 13, 2020 Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe Jun 29, 2020 Ovid Therapeutics Added to Russell 2000® and Russell 3000® Indexes Jun 19, 2020 Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome Jun 11, 2020 Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
